Biorestorative Therapies, Inc. · NASDAQ:BRTX
Biorestorative Therapies — Investor Presentation (August 2025)
27 slides from Biorestorative Therapies's investor presentation, Aug 14, 2025
Slide 1: Regenerative Biology for Healthier Lives
pinrestoraive therapies Regenerative Biology for Healthier Lives Investor Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements in this presentation, including the information set forth as to the future financial or operating performance of Biorestorative Therapies, Inc. (the “Company’) that are not current or historical factual statements may constitute “forward-looking” information wit
Slide 3: Fully Integrated Regenerative Medicine Company
Fully Integrated Regenerative Medicine Company DEVELOPMENT COMMERCIAL ThermoStem BRTX=100. BioCosmeceuticals Brown adipose derived Bone marrow derived Secretome (novel SxesoMme, stem cells mesenchymal stem cells growth factor/cytokine) biologics based technology PRECLINICAL MID-STAGE CLINICAL for co
Slide 4: Experienced Leadership
Experienced Leadership Lance Alstodt Robert Kristal Chairman & CEO Chief Financial Officer _ 30+ years leading, advising and operating companies within the + 25+ years on Bay Street and Wall Street Healthcare sector + Most recently was the DOR for a Healthcare focused Investment Bank ReMinelef GH Me
Slide 5: Commercial
COMMERCIAL ThermoStem BRTX-100 BioCosmeceuticals Secretome (novel exosome, growth factor/cytokine) biologics based technology for cosmetic applications biorestordtve
Slide 6: Going Commercial: Biologics Based Cosmetic Products
Going Commercial: Biologics Based Cosmetic Products The Market OV. * Global Cosmetic market $63 B and growing 0) * Global injectable market 12% CAGR 2021-2026 Est $11.9 B SS + Derms need differentiated product * Bundle with current procedures Key Features of Cosmetics & Manufacturing Hair Growth * C
Slide 7: Development
DEVELOPMENT ThermoStem BRTX=100 Brown adipose derived Bone marrow derived stem cells mesenchymal stem cells PRECLINICAL CLINICAL biorestordtlve
Slide 8: Robust Preclinical & Clinical Pipeline
Robust Preclinical & Clinical Pipeline PRECLINICAL PHASE1 PHASE 2 PHASE 3 COMMERCIAL FAST a a ° “4 2 Hips/Knees . =< Musculoskeletal Extremities [ System Avascular Zones fr Metabolic Obesity fr Q a 8 =| Brown Adipose Stem Cells . Long Hauler Covid . Polycystic ovarian syndrome biorestorat
Slide 9: Chronic Lumbar Disc Disease (cLDD) U.S. adult population
Chronic Lumbar Disc Disease (cLDD) 258 M U.S. adult population 64 5 M American adults with chronic e lower back pain prevalence 32 M American adults with diagnosed and treated disc degeneration 1 5 M Americans suffering pain caused by a protruding or injured disc 2 5 M Invasive Surgical Procedures p
Slide 10: The Problem: Clinical & Economic
The Problem: Clinical & Economic Conservative Surgical Treatments Treatments ORAL BEDICATIONS SEG \ SPINAL FUSION SURGERY $1,000 - $2,000 jn, y $110,000 INJECTION TREATMENT VS a wk DISCECTOMY $8,000 jn UNMET NEED $20,000 - arene Serta ERR SSEEes PHYSICAL MEASURES Y NN DISC REPLACEMENT SURGERY $20,00
Slide 11: Our Solution: BRTX-100
Our Solution: BTRX-100 Conservative Treatments ORAL MEDICATION TREATMENT J opioips $1,000 - $2,000 ,.,., INJECTION TREATMENT $8,000 .... $2,000 per injection, 2 injections per treatment-semi-annual treatment PHYSICAL MEASURES $20,000 j.ruary $200 per session, 2 sessions per week Often Recurrent @ No
Slide 12: BRTX-100: Clinical Snapshot
BRTX-100: Clinical Snapshot Lead investigational therapeutic product ty aap @} e Autologous Hypoxic (low oxygen) Single intradiscal injection (patient’s own) cultured, bone — anticipated 30 minute cell-based biologic marrow-derived in-office procedure * ow.) al al Prior human data provides Ongoing F
Slide 13: BRTX-100: Key Differentiating Factors
BRTX-100: Key Differentiating Factors SOURCE CULTURING CARRIER MANUFACTURING pmesoblast Allogeneic uses human derived stem cells (not from patient) - 6 million Normoxic cultured with normal oxygen environment (~20%) Hyaluronic Acid Carrier Animal Products Used biwederde a Autologous uses patients ow
Slide 14: BRTX-100: Positive Human Data
BRTX-100: Positive Human Data Human data from studies of therapies similar to BRTX-100 show reduced pain, increased function, and an absence of significant safety issues with a durable response sorossastaratt Sosy =” jouer Translational Medicine RESEARCH Treatment of lumbar degenerative disc disease
Slide 15: BRTX-100 in cLDD: Phase 2 Trial Design
BRTX-100 in cLDD: Phase 2 Trial Design FDA Cleared IND 17275: Phase 2 Randomized, Controlled Study Design in Patients with cLDD Design * Study includes 99 subjects (2:1 product to placebo) * 40.000.000 cells/dose + Included subjects will have only one symptomatic diseased disc Primary Efficacy Endpo
Slide 16: BRTX-100: Logistical/Clinical Process
BRTX-100: Logistical /Clinical Process Collection Collection and Shipment of Patient's Bone Marrow and Blood to Cell Production Manufacturer Production Production of BRTX-100 Hypoxic BRTX-100 Culturing of Stern Cells Production Process Clinical Site Thawing and Injection of BRTX-100 into Patient's D
Slide 17: BRTX-100: Cleared DSMB June 2023
BRTX-100: Cleared DSMB June 2023 Unanimous approval by the DSMB to continue trial without changes 3:1 randomization BRTX-100 is safe and well tolerated No Significant Adverse Events All 4 subjects successfully dosed with either 40 mil NMSCs or placebo VAS, ODI, SF-12, RMDQ, and FRI scores to measure
Slide 18: Compelling Preliminary Phase 2 Clinical Data
Compelling Preliminary Phase 2 Clinical Data (36 Subjects): Meaningful Signals 80% 40% 20% 0% 52 weeks mmm Average improvement in VAS versus baseline mmm Average improvement in ODI versus baseline ——Level of improvement required by the FDA Presented at ISSCR 2025 FDA is requiring at least a greater
Slide 19: ThermoStem Program: Allogeneic Cell-based Therapy
ThermoStem Program: Allogeneic Cell-based Therapy Target Conditions: Obesity, Type 2 diabetes, and Metabolic disorders Cell Type: Brown Fat * Has been shown to regulate metabolic homeostasis in the body Components of Library: + Human Brown Adipose Tissue (BAT) * White Adipose Tissue (WAT) * Brown Ad
Slide 20: Metabolic Program Highlights
Metabolic Program Highlights First human stem cell derived BAT transfer Creation of first human 3D engineered artificial brown WHITE FAT adipose tissue construct (aBAT) Saeaera:: Sos & i em LE, BEIGE FAT iS Successful delivery of 3D aBAT construct in mouse model —e i BY, ye Transplantation of aBAT l
Slide 21: File DMF / Pre-IND Meeting / Phase 1/2 Trial
File DMF with FDA Expect filing a Drug Master File ("DMF") with the FDA to facilitate licensing opportunities around ThermoStem. Initiate Phase 1/2 Clinical Trial Pre-IND Meeting Upon FDA approval commence with FDA Phase 1/2 clinical trial. Scheduling Pre-IND meeting with FDA to discuss first-in-man
Slide 22: Our Opportunities are Well-Protected
Our Opportunities are Well-Protected PROGRAM INDICATION PATENT TITLES STATUS NO. OF APPLICATIONS Disc / Spine + Methods and Compositions to facilitate repair of avascular tissue + Surgical Methods and Compositions to facilitate repair of avascular tissue + Therapeutic Delivery Device 4 2 Issued 2 Pe
Slide 23: Scientific Advisory Board
Scientific Advisory Board Wayne Marasco, MD, PDt Chairman of SAB Principal Faculty Member of Harvard Stem Cell Institute Professor in the Department of Cancer Immunology & AIDS at the Dana-Farber Cancer Institute Professor of Medicine at Harvard Medical School Wayne Olan, MD Clinical Director of Reg
Slide 24: Financial Summary
Financial Summary CURRENT CAPITALIZATION SHARES Common Shares Outstanding Common Shares Including Abeyance Preferred Series B Shares Outstanding Cash Debt 8.0 Million® 9.1 Million** Convertible to 1.4 Million Common** $7.4 Million** $0 * As of 08/11/2025 ** As of 06/30/2025 b iorestordtlve
Slide 25: Recent Accomplishments
Recent Accomplishments v v SSNS OK <x Announced FDA clearance of important BRTX-100 clinical study protocol amendment (replaces saline injection with sham injection in control arm) Reported positive preliminary Phase 2 BRTX-100 study data (36 patient) in cLDD Received FDA Fast Track Designation for
Slide 26: In Conclusion
In Conclusion cGMP ISO-7 Certified Clean room Addressing Multi-Billion Dollar Markets with Unmet Needs Disruptive Platform Technologies in Cellular Therapy Opportunity for Key Strategic Partnerships in Cosmetic Space 6 6 6 G6 Strong Preliminary Data Indicative of Positive Trial Outcomes Active Phase
Slide 27: Piciectorve
Piciectorve therapies 40 Marcus Drive, Suite 1 Melville, NY 11747 (631) 760-8100 biorestorative.com
BioRestorative Therapies — Investor Presentation (August 2025) on 6ix